Studies have shown that CTLA-4 monoclonal antibody combined with thermal ablation in the treatment of advanced PLC can significantly reduce the viral load of patients with hepatitis BLC, down regulate Treg cells in TME, increase the infiltration of CD8+T cells in tumor site, and increase the survival rate of patients with advanced PLC, the 6-month and 12-month DFS rates were 57.1 and 33.1%, respectively (Duffy et al., 2017; Kudo and Masatoshi, 2017). This evidence concerns the gene CD8A and neoplasm.